何奇志女士
- 小核酸药物公司 首席执行官
何奇志女士（Kathy He）是小核酸药物公司Lerna Biopharma Pte.（以下简称 "Lerna"）的首席执行官。Lerna是一家初创型创新药物研发公司。借助于上海、波士顿和新加坡三地的资本，技术和人才优势，结合团队对生物靶点的深入理解以及多年核酸药物化学的行业经验，Lerna专注研发针对肝部疾病的first-in-class 的核酸药物。Kathy在中、美医药行业从事管理运营，产品开发及市场推广20多年，曾成功推动了多款创新药物进入市场，在优化产品组合及企业战略发展上拥有丰富的经验，同时还具备全球化研发运营管理背景。加入Lerna之前，Kathy是科越医药（Kira Pharmaceuticals）的全球首席商务官及中国区总经理，任职期间，她带领该公司完成6,000万美元的B+轮融资，并帮助科越医药在中国搭建了高效的运营体系，助力其全球化扩张。Kathy还曾是香港上市公司和誉生物（Abbisko Therapeutics）的首席商务官和企业发展负责人，主导其早期超过1亿美元的融资，为和誉生物建立了多个跨境战略合作伙伴关系。此外，Kathy曾在包括武田制药（Takeda）、默沙东（MSD）和雅培（Abbott）等数家跨国医药公司负责多款重磅药物在美国的市场推广。除丰富的行业运营经验外，Kathy还曾在知名投资公司担任企业合伙人。
Prior to joining Lerna, Ms. He was the Chief Business Officer (CBO) and General Manager at Kira Pharmaceuticals, where she led the closing of its $60M Series B+ round of financing and built an operation in China to support Kira’s global expansion. Before Kira, she was the CBO and Head of Corporate Development at Abbisko Therapeutics (HKEx stock code: 02256), where she led the raise of over $100M and closed a series of cross-border strategic partnerships. In addition to her extensive operating experience, Kathy also worked as a Venture Partner and Managing Director at top tier investment firms in China.
Kathy received a BS degree in biology from Wuhan University, a MS in molecular biology from University of Illinois at Urbana-Champaign, and MBA from Kellogg School of Management at Northwestern University. She is currently a board member of Diagnostic Photonics, an innovative medical device company, a former trustee of Illinois Mathematics and Science Academy, and a past board member of the BayHelix Group, a non-profit professional organization for business leaders in life sciences and healthcare industries.